Somatostatin receptor radionuclide therapy in neuroendocrine tumors

被引：19

作者：

Haider, Mintallah ^{[1
]}

Das, Satya ^{[2
]}

Al-Toubah, Taymeyah ^{[1
]}

Pelle, Eleonora ^{[3
]}

El-Haddad, Ghassan ^{[4
]}

Strosberg, Jonathan ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept GI Oncol, Tampa, FL 33612 USA

[2] Vanderbilt Univ, Dept GI Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA

[3] Univ Bari, Dept Oncol, Bari, Puglia, Italy

[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Diagnost Imaging & Intervent Radiol, Tampa, FL USA

来源：

关键词：

neuroendocrine tumors; peptide receptor radionuclide therapy; PRRT; (177)Lutetium-DOTATATE; radiolabeled somatostatin analog;

D O I：

10.1530/ERC-20-0360

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peptide receptor radionuclide therapy (PRRT) using Lu-177-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review summarizes study data supporting the use of radiolabeled somatostatin analogs for the treatment of advanced NETs and highlights risks, including potential toxicities in specific populations. Key ongoing clinical trials, including randomized studies, are designed to better define the position of PRRT within the broader therapeutic landscape. Preclinical and early-phase human studies are focused on the development of novel somatostatin-receptor agonists and antagonists, new radionuclides, and radiosensitizing combination therapies.

引用

页码：R81 / R93

页数：13

共 72 条

[1] Combination of everolimus and lu-177 PRRT in treatment of G1-2 neuroendocrine tumors (NET): Phase 1-2 study. [J].

Aljubran, Ali Husain ;

Alrowaili, Mohamed ;

Raef, Hussein ;

Bazarbashi, Shouki ;

Alzahrani, Ahmed M. ;

Almuhaideb, Ahmed ;

Almanea, Hadeel ;

Badran, Ahmed Ali ;

Al-Dalee, Abdelmuniem ;

Tuli, Mahmoud .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

[2] Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety [J].

Ballal, Sanjana ;

Yadav, Madhav Prasad ;

Bal, Chandrasekhar ;

Sahoo, Ranjit Kumar ;

Tripathi, Madhavi .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) :934-946

[3] Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study [J].

Ballal, Sanjana ;

Yadav, Madhav P. ;

Damle, Nishikant A. ;

Sahoo, Ranjit K. ;

Bal, Chandrasekhar .

CLINICAL NUCLEAR MEDICINE, 2017, 42 (11) :E457-E466

[4]

Baum Richard P, 2018, Oncotarget, V9, P16932, DOI 10.18632/oncotarget.24524

[5] PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy [J].

Bodei, Lisa ;

Kidd, Mark S. ;

Singh, Aviral ;

van der Zwan, Wouter A. ;

Severi, Stefano ;

Drozdov, Ignat A. ;

Cwikla, Jaroslaw ;

Baum, Richard P. ;

Kwekkeboom, Dik J. ;

Paganelli, Giovanni ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (07) :1155-1169

[6] Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors [J].

Bodei, Lisa ;

Kidd, Mark ;

Paganelli, Giovanni ;

Grana, Chiara M. ;

Drozdov, Ignat ;

Cremonesi, Marta ;

Lepensky, Christopher ;

Kwekkeboom, Dik J. ;

Baum, Richard P. ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) :5-19

[7] Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial) [J].

Braat, Arthur J. A. T. ;

Kwekkeboom, Dik J. ;

Kam, Boen L. R. ;

Teunissen, Jaap J. M. ;

de Herder, Wouter W. ;

Dreijerink, Koen M. A. ;

van Rooij, Rob ;

Krijger, Gerard C. ;

de Jong, Hugo W. A. M. ;

van den Bosch, Maurice A. A. J. ;

Lam, Marnix G. E. H. .

BMC GASTROENTEROLOGY, 2018, 18

[8] Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors [J].

Brabander, Tessa ;

van der Zwan, Wouter A. ;

Teunissen, Jaap J. M. ;

Kam, Boen L. R. ;

Feelders, Richard A. ;

de Herder, Wouter W. ;

van Eijck, Casper H. J. ;

Franssen, Gaston J. H. ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

CLINICAL CANCER RESEARCH, 2017, 23 (16) :4617-4624

[9] 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide [J].

Bushnell, David L., Jr. ;

O'Dorisio, Thomas M. ;

O'Dorisio, M. Sue ;

Menda, Yusuf ;

Hicks, Rodney J. ;

Van Cutsem, Eric ;

Baulieu, Jean-Louis ;

Borson-Chazot, Francoise ;

Anthony, Lowell ;

Benson, Al B. ;

Oberg, Kjell ;

Grossman, Ashley B. ;

Connolly, Mary ;

Bouterfa, Hakim ;

Li, Yong ;

Kacena, Katherine A. ;

LaFrance, Norman ;

Pauwels, Stanislas A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1652-1659

[10] Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line [J].

Cambiaghi, Valeria ;

Vitali, Eleonora ;

Morone, Diego ;

Peverelli, Erika ;

Spada, Anna ;

Mantovani, Giovanna ;

Lania, Andrea Gerardo .

ENDOCRINE, 2017, 56 (01) :146-157

← 1 2 3 4 5 6 7 8 →